NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
In the version of this article initially published, the numbers in the 'R sym ' row in Table 1 are in the wrong columns. The error has been corrected in the HTML and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of ...
Clone size and symptom burden dictate how often patients with PNH require follow-up. Hematology assessments during routine visits should include flow cytometry, CBC, D-dimer levels, and serum ferritin ...
November 21, 2011 — The cartilage damage associated with osteoarthritis (OA) is in part a result of dysregulation of the complement system, Qian Wang, MD, PhD, and colleagues reported in an article ...
Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Geographic atrophy area growth was significantly slower ...
The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback